AJP - Heart Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 297: H1032-H1039, 2009. First published July 10, 2009; doi:10.1152/ajpheart.00374.2009
0363-6135/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/3/H1032    most recent
00374.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ansari, H. R.
Right arrow Articles by Mustafa, S. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ansari, H. R.
Right arrow Articles by Mustafa, S. J.

A1 adenosine receptor-mediated PKC and p42/p44 MAPK signaling in mouse coronary artery smooth muscle cells

Habib R. Ansari,1 Bunyen Teng,1 Ahmed Nadeem,1 Kevin P. Roush,1 Karen H. Martin,2 J. Schnermann,3 and S. Jamal Mustafa1

1Department of Physiology and Pharmacology, Center for Cardiovascular and Respiratory Sciences, and 2Microscope Imaging Facility, Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia; and 3National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Submitted 20 April 2009 ; accepted in final form 2 July 2009

The A1 adenosine receptor (A1AR) is coupled to Gi/Go proteins, but the downstream signaling pathways in smooth muscle cells are unclear. This study was performed in coronary artery smooth muscle cells (CASMCs) isolated from the mouse heart [A1AR wild type (A1WT) and A1AR knockout (A1KO)] to delineate A1AR signaling through the PKC pathway. In A1WT cells, treatment with (2S)-N6-(2-endo-norbornyl)adenosine (ENBA; 10–5M) increased A1AR expression by 150%, which was inhibited significantly by the A1AR antagonist 1,3-dipropyl-8-cyclopentylxanthine (10–6M), but not in A1KO CASMCs. PKC isoforms were identified by Western blot analysis in the cytosolic and membrane fractions of cell homogenates of CASMCs. In A1WT and A1KO cells, significant levels of basal PKC-{alpha} were detected in the cytosolic fraction. Treatment with the A1AR agonist ENBA (10–5M) translocated PKC-{alpha} from the cytosolic to membrane fraction significantly in A1WT but not A1KO cells. Phospholipase C isoforms (βI, βIII, and {gamma}1) were analyzed using specific antibodies where ENBA treatment led to the increased expression of PLC-βIII in A1WT CASMCs while having no effect in A1KO CASMCs. In A1WT cells, ENBA increased PKC-{alpha} expression and p42/p44 MAPK (ERK1/2) phospohorylation by 135% and 145%, respectively. These effects of ENBA were blocked by Gö-6976 (PKC-{alpha} inhibitor) and PD-98059 (p42/p44 MAPK inhibitor). We conclude that A1AR stimulation by ENBA activates the PKC-{alpha} signaling pathway, leading to p42/p44 MAPK phosphorylation in CASMCs.

A1 adenosine receptor agonist; coronary artery smooth muscle; protein kinase C; mitogen-activated protein kinase signaling


Address for reprint requests and other correspondence: S. J. Mustafa, Dept. of Physiology and Pharmacology, Center for Cardiovascular and Respiratory Sciences, Robert C. Byrd Health Science Center, School of Medicine, West Virginia Univ., Morgantown, WV 26506 (e-mail: smustafa{at}hsc.wvu.edu)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.